Key emerging themes for assessing the cost-effectiveness of reporting incidental findings

Genetics in Medicine

Volumn 17, Issue 4, 2015, Pages 314-315

  Phillips, Kathryn A ^a   Ladabaum, Uri ^b,c   Pletcher, Mark J ^c,d   Marshall, Deborah A ^c,e   Douglas, Michael P ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Department of Clinical Pharmacy ^*  (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; FAMILIAL HYPERCHOLESTEROLEMIA; GENETIC SCREENING; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; INCIDENTAL FINDING; LETTER; NEXT GENERATION SEQUENCING; OVARY CANCER; PERSONALIZED MEDICINE; CLINICAL EFFECTIVENESS; LIFE EXPECTANCY; PREVALENCE; ECONOMICS; FEMALE; GENOMICS; HIGH THROUGHPUT SEQUENCING; MALE; PROCEDURES;

FEMALE; GENOMICS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE;

EID: 84926431306     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.2015.13     Document Type: Letter

References (4)

1. Bennette CS, Gallego CJ, Burke W, Jarvik GP, Veenstra DL. The cost-effectiveness of returning incidental findings from next-generation genomic sequencing. Genet Med; e-pub ahead of print 13 November 2014.
2. Phillips KA, Trosman JR, Kelley RK, Pletcher MJ, Douglas MP, Weldon CB. Genomic sequencing: assessing the health care system, policy, and big-data implications. Health Aff (Millwood) 2014;33:1246-1253.
3. Gold MR. Cost-Effectiveness in Health and Medicine. Oxford University Press: New York, 1996.
4. Vegter S, Boersma C, Rozenbaum M, Wilffert B, Navis G, Postma MJ. Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: a systematic review on content and adherence to guidelines. Pharmacoeconomics 2008;26:569-587.